Synonyms: PT-141 | PT141 | Vyleesi®
bremelanotide is an approved drug (FDA (2019))
Compound class:
Peptide
Comment: Bremelanotide is a stabilised, cyclic derivative of αMSH. Although it exhibits little selectivity across the melanocortin receptor family (with the exception of MC2, the ACTH receptor), bremelanotide's ability to increase female sexual arousal/desire is attributed primarily to agonist activity at the MC3 and MC4 receptors [3].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
A subcutaneous injectible form of bremelanotide is approved as a treatment for premenopausal women suffering from hypoactive sexual desire disorder (HSDD). |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Agonist activity at the MC3 and MC4 receptors is thought to underlie bremelanotide's downstream CNS effects of increasing arousal and desire [3]. |